Abstract
Long-Term Outcome of Treatment-Naïve and Relapsed/Refractory Patients with CLL and TP53 Aberrations Treated with Ibrutinib, with or without Rituximab
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have